Meridian Bioscience Inc. Aktie
-
Deine Einschätzung
Meridian Bioscience Inc. Aktie
Was spricht für und gegen Meridian Bioscience Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Meridian Bioscience Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Meridian Bioscience Inc. | - | - | - | - | - | - | - |
| SI-BONE Inc | -0,89 % | -4,31 % | 4,72 % | -11,20 % | -34,32 % | - | - |
| Lantheus Holdings Inc | 0,28 % | 0,70 % | 11,01 % | -19,83 % | 25,52 % | -7,04 % | - |
| Lemaitre Vascular Inc | -2,04 % | -1,54 % | 0,00 % | 21,52 % | 36,17 % | - | - |
Kommentare
News
Atlas Energy Stock Jumps 39% YTD, but One Fund Cut Exposure by $15 Million Last Quarter
On February 17, 2026, Meridian Wealth Advisors disclosed a reduction in its Atlas Energy Solutions (NYSE:AESI) position, selling 1,458,193 shares for an estimated $14.74 million based on average
This REIT Is Down 60% Since 2006, but a $9.2 Million Bet Says There’s Still Value
New York City-based DSC Meridian Capital initiated a new position in Elme Communities (NYSE:ELME), acquiring 543,081 shares valued at approximately $9.2 million, according to a November 14 SEC
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year
New York City-based DSC Meridian Capital fully exited its position in Bausch + Lomb during the third quarter, reducing its holdings by 510,090 shares, a move totaling approximately $6.6 million.




